{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T19:49:31Z","timestamp":1794772171884,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Fujian Province of China","award":["2021J011387"],"award-info":[{"award-number":["2021J011387"]}]},{"name":"Sanming Science and Technology Project","award":["2024-S-084"],"award-info":[{"award-number":["2024-S-084"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Distant metastasis remains the leading cause of mortality in breast cancer, yet comprehensive population-based evaluations of metastatic site combinations and their survival implications are limited. This study aimed to explore the clinicopathological determinants and prognostic outcomes of site-specific and multi-organ metastases in breast cancer using SEER data. A total of 200,558 female breast cancer patients diagnosed between 2014 and 2023 were extracted from the SEER database. Logistic regression was used to assess associations between clinicopathological features and metastatic patterns. Kaplan\u2013Meier analysis and Cox proportional hazards models were applied to evaluate overall survival (OS) across different metastatic site combinations. Among patients with distant metastasis classified into 15 common metastatic patterns, bone was the most common metastatic site (21.3%), followed by lung (16.1%), liver (9.2%), and brain (2.9%). Molecular subtypes showed distinct organotropism: HR+\/HER2\u2009\u2212\u2009tumors were prone to bone-only metastasis, whereas HER2-positive and triple-negative subtypes were more likely to involve visceral and brain metastases. Multi-organ metastases, especially combinations including the brain (e.g., brain\u2009+\u2009liver\u2009+\u2009lung), were associated with the poorest prognosis (median OS: 4.0 months). Younger age (\u2264\u200940 years), higher histological grade (Grade III), and tumor location in the axillary tail or unspecified regions were independently associated with increased metastatic risk. Grade III tumors exhibited broader visceral spread and significantly worse survival compared to lower-grade tumors. This is the first population-based study to systematically characterize 15 metastatic site combinations and their survival outcomes across molecular subtypes. The findings highlight the heterogeneity of breast cancer metastasis and underscore the need for subtype-specific, site-targeted surveillance strategies and prognostic assessment tools.<\/jats:p>","DOI":"10.1038\/s41598-025-12883-x","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T02:52:13Z","timestamp":1753239133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Patterns and prognostic implications of distant metastasis in breast Cancer based on SEER population data"],"prefix":"10.1038","volume":"15","author":[{"given":"Maoquan","family":"zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"3","key":"12883_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"Cancer J. Clin."},{"issue":"20","key":"12883_CR2","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol.28(20), 3271\u20133277 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"12883_CR3","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","volume":"68","author":"M Smid","year":"2008","unstructured":"Smid, M. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res.68(9), 3108\u20133114 (2008).","journal-title":"Cancer Res."},{"issue":"12","key":"12883_CR4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1634\/theoncologist.2011-0196","volume":"16","author":"J Li","year":"2011","unstructured":"Li, J. et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist16(12), 1675\u20131683 (2011).","journal-title":"Oncologist"},{"issue":"10","key":"12883_CR5","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/cncr.23930","volume":"113","author":"NU Lin","year":"2008","unstructured":"Lin, N. U. et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer113(10), 2638\u20132645 (2008).","journal-title":"Cancer"},{"issue":"1","key":"12883_CR6","first-page":"33","volume":"2","author":"JP Leone","year":"2015","unstructured":"Leone, J. P. & Leone, B. A. Breast cancer brain metastases: incidence, treatment, and survival. Interdisciplinary Neurosurg. 2 (1), 33\u201335 (2015).","journal-title":"Interdisciplinary Neurosurg."},{"issue":"3","key":"12883_CR7","first-page":"563","volume":"19","author":"N Niikura","year":"2014","unstructured":"Niikura, N. et al. Spread pattern of bone metastasis in breast cancer. Int. J. Clin. Oncol. 19 (3), 563\u2013568 (2014).","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"12883_CR8","doi-asserted-by":"crossref","first-page":"18625","DOI":"10.1038\/s41598-020-75490-y","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Clinicopathological features and survival analysis in breast cancer patients with distant organ metastasis: A SEER-based study. Sci. Rep. 10 (1), 18625 (2020).","journal-title":"Sci. Rep."},{"issue":"12","key":"12883_CR9","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/cam4.2474","volume":"8","author":"H Dillek\u00e5s","year":"2019","unstructured":"Dillek\u00e5s, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 8 (12), 5574\u20135576 (2019).","journal-title":"Cancer Med."},{"issue":"9","key":"12883_CR10","first-page":"1825","volume":"117","author":"ND Arvold","year":"2011","unstructured":"Arvold, N. D. et al. Brain metastases after breast-conserving therapy: associations with molecular subtype. Cancer 117 (9), 1825\u20131832 (2011).","journal-title":"Cancer"},{"issue":"6","key":"12883_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2010.33.8889","volume":"30","author":"N Niikura","year":"2012","unstructured":"Niikura, N. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol.30(6), 593\u2013599 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"7249","key":"12883_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature459(7249), 1005\u20131009 (2009).","journal-title":"Nature"},{"issue":"6","key":"12883_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr1612","volume":"8","author":"R Nahta","year":"2006","unstructured":"Nahta, R. & Esteva, F. J. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res.8(6), 215 (2006).","journal-title":"Breast Cancer Res."},{"issue":"6","key":"12883_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","volume":"3","author":"Y Kang","year":"2003","unstructured":"Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell.3(6), 537\u2013549 (2003).","journal-title":"Cancer Cell."},{"key":"12883_CR15","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.920432","volume":"26","author":"Y Gu","year":"2020","unstructured":"Gu, Y. et al. Prognostic value of site-specific metastases and surgery in de novo stage IV triple-negative breast cancer: A population-based analysis. Med. Sci. Monit.26, e920432 (2020).","journal-title":"Med. Sci. Monit."},{"key":"12883_CR16","first-page":"904397","volume":"12","author":"X Jin","year":"2022","unstructured":"Jin, X. et al. Survival analysis of patients with breast cancer and different patterns of distant metastasis: A SEER-based study. Front. Oncol. 12, 904397 (2022).","journal-title":"Front. Oncol."},{"key":"12883_CR17","first-page":"2873","volume":"10","author":"SG Wu","year":"2018","unstructured":"Wu, S. G. et al. Patterns of distant metastasis between different histological types of breast cancer. Cancer Manage. Res. 10, 2873\u20132880 (2018).","journal-title":"Cancer Manage. Res."},{"issue":"1","key":"12883_CR18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12885-023-10565-3","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Different distant metastasis patterns and survival outcomes in breast cancer patients: a population-based study. BMC Cancer. 23 (1), 81 (2023).","journal-title":"BMC Cancer"},{"issue":"4","key":"12883_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3348\/kjr.2010.11.4.490","volume":"11","author":"KE Cho","year":"2010","unstructured":"Cho, K. E. et al. Clear cell hidradenoma of the axilla: A case report with literature review. Korean J. Radiol.11(4), 490\u2013492 (2010).","journal-title":"Korean J. Radiol."},{"key":"12883_CR20","doi-asserted-by":"crossref","first-page":"18650","DOI":"10.1038\/s41598-020-75644-y","volume":"10","author":"X Li","year":"2020","unstructured":"Li, X. et al. Distant metastasis pattern and prognosis of breast cancer patients with different histological grades: A SEER-based study. Sci. Rep. 10, 18650 (2020).","journal-title":"Sci. Rep."},{"issue":"3","key":"12883_CR21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.21147\/j.issn.1000-9604.2020.03.05","volume":"32","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Impact of neoadjuvant chemotherapy on the immune microenvironment of triple-negative breast cancer. Chin. J. Cancer Res. 32 (3), 405\u2013413 (2020).","journal-title":"Chin. J. Cancer Res."},{"issue":"3","key":"12883_CR22","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/bcr767","volume":"6","author":"G Arpino","year":"2004","unstructured":"Arpino, G. et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 6 (3), R149\u2013156 (2004).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"12883_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli, M. et al. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J. Clin. Oncol.23(1), 41\u201348 (2005).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12883-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12883-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12883-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:56:42Z","timestamp":1757271402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12883-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12883"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12883-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based on the publicly available SEER database. Since the data are de-identified and do not involve any interaction with human subjects, ethical approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26717"}}